November 19, 2009
 FDA Approval Letter to Bristol-Myers Squibb for the Pediatric Use of Abilify to Treat Irritability Associated With Autism
The U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application for Abilify (aripiprazole) to treat irritability associated with autism in
children aged six to 17. The approval was based on the results of two eight-week, randomized, double-blind placebo-controlled studies which compared the
effectiveness of Abilify in reducing irritability and aggression to a placebo.
| 
To download the file in PDF format, you first need to download the free Adobe Acrobat Viewer. The Acrobat Viewer will
launch the file so that you can see the document and/or print it.